GLAXOSMITHKLINE PLC Form 6-K/A July 26, 2017

FORM 6-K / A

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending 26 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

The following amendment has been made to the Director/PDMR Shareholding announcement released on 27 April 2017 in respect of the volume of notional Ordinary Shares acquired by Mr Urs Rohner (Independent Non-Executive Director) under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

Price(s) and volume(s) Price(s) Volume(s) £15.83 454.043

All other details remain unchanged.

The full amended text is shown below.

GlaxoSmithKline plc (the 'Company')

Transaction notification

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Philip Hampton
 b) Position/status Non-Executive Chairman
 c) Initial notification/ amendment Initial notification
 c) Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of the financial instrument

b)	Nature of the transaction	Ordinary S share alloc for Indeper Non-Exect the period January 20	n of notional Shares under the sation arrangements ndent utive Directors for of service from 1 017 to 31 March
c)	Price(s) and volume(s)	2017. Price(s) £15.83 n/a (single	Volume(s) 2,763.740 transaction)
d)	Aggregated information		

Aggregated volume Price

e)	Date of the transaction	2017-04-26
f)	Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Professor Sir Roy Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.	

Price(s) Price(s) and Volume(s) volume(s) £15.83 454.043 n/a (single transaction)

Aggregated information

d)

c)

Aggregated volume Price

e)	Date of the transaction	2017-04-26
f)	Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr Vindi Banga	
b)	Position/status	Senior Independent	
0)		Non-Executive Director	
-)	Initial notification/		
c)	amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
Ζ.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b	e repeated for (i) each type of	
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each	
	place where transaction(s) has been conducted		
	-	Ordinary shares of 25 pence	
		each ('Ordinary Shares')	
,		ISIN: GB0009252882	
- a)	Description of the financial instrument		

a) Description of the financial instrument

	Acquisition of notional
	Ordinary Shares under the
	share allocation arrangements
h) Nature of the transportion	for Independent
b) Nature of the transaction	Non-Executive Directors for
	the period of service from 1
	January 2017 to 31 March
	2017.
Price(s) and	Price(s) Volume(s)
c) volume(s)	£15.83 1,816.172
	n/a (single transaction)
Aggregated information	

d)

Aggregated volume Price

e)	Date of the transaction	2017-04-26
f)	Place of the transaction	n/a

1.	Details of PDMR/	person closely	associated	with them	('PCA')

1.	Details of I Diving person closery associa	
a)	Name	Dr Vivienne Cox
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
		Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent

b) Nature of the transaction

share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s)

	Lugar i iirig.	
	volume(s)	£15.83 335.597 n/a (single transaction)
4)	Aggregated information	
d)	Aggregated volume Price	
e)	Date of the transaction	2017-04-26
f)	Place of the transaction	n/a
1.	Details of PDMR/person closely associa	ted with them ('PCA')
	Name	Ms Lynn Elsenhans
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction;	(iii) each date; and (iv) each
	place where transaction(s) has been cond	
		American Depositary Shares ('ADSs')
a)	Description of the financial instrument	ISIN: US37733W1053
		Acquisition of notional ADSs under the share allocation
		arrangements for Independent
b)	Nature of the transaction	Non-Executive Directors for
		the period of service from 1 January 2017 to 31 March
		2017.
c)	Price(s) and	Price(s) Volume(s)
0)	volume(s)	\$41.13 1,202.913
		n/a (single transaction)
	Aggregated information	
<i>d</i>)		

d)

Aggregated volume Price

- e) Date of the transaction
- f) Place of the transaction

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Dr Jesse Goodman
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
		American Depository Shares

American Depositary Shares ('ADSs') ISIN: US37733W1053

a) Description of the financial instrument

Dr Jesse Goodman was appointed to the Board with effect from 1 January 2016, as previously announced, and in accordance with the share allocation arrangements for Independent Non-Executive Directors, 25% of his fees were retained to be reinvested in notional ADSs at a date to be mutually agreed. The accumulated balance of the retained fees has now b) Nature of the transaction been reinvested as disclosed below. Going forward, notional ADSs of the Company will be allocated on a quarterly basis. Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2017. Price(s) and Price(s) Volume(s) c) volume(s) \$41.13 1,739.846

Aggregated information d)	n/a (single transaction)
Aggregated volume Price	
e) Date of the transaction	2017-04-26
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Ms Judy Lewent	
b) Position/status	Independent Non-Executive Director	
c) Initial notification/ amendment	Initial notification	
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b) LEI	5493000HZTVUYLO1D793	
Details of the transaction(s): section to be repeated for (i) each type of		
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
_	American Depositary Shares	
	('ADSs')	
a) Description of the financial instrument	ISIN: US37733W1053	

b) Nature of the transaction	Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.	
c) Price(s) and volume(s)	Price(s) Volume(s) \$41.13 449.364 n/a (single transaction)	
Aggregated information		

d)

Aggregated volume Price

e) Date of the transaction	2017-04-26
f) Place of the transaction	n/a

a)	Name	Mr Urs Rohner			
h)	Position/status	Independent Non-Executive			
0)	1 Osition/status	Director			
	Initial notification/	A			
c)	amendment	Amendment			
	Details of the issuer, emission allowance	s of the issuer, emission allowance market participant, auction			
2.	platform, auctioneer or auction monitor				
a)	Name	GlaxoSmithKline plc			
	LEI	5493000HZTVUYLO1D793			
b)					
	Details of the transaction(s): section to b				
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each				
	place where transaction(s) has been cond	ducted			
		Ordinary shares of 25 pence			
	Description of the financial instrument	each ('Ordinary Shares')			
a)					
	I I I I I I I I I I I I I I I I I I I				
		Acquisition of notional			
		Acquisition of notional			
		Ordinary Shares under the			
		Ordinary Shares under the share allocation arrangements			
b)	Nature of the transaction	Ordinary Shares under the share allocation arrangements for Independent			
b)	Nature of the transaction	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for			
b)	Nature of the transaction	Ordinary Shares under the share allocation arrangements for Independent			
b)	Nature of the transaction	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for			
b)	Nature of the transaction	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1			
		Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.			
b) c)	Price(s) and	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s)			
		Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s) £15.83 454.043			
	Price(s) and	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s)			
	Price(s) and volume(s)	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s) £15.83 454.043			
c)	Price(s) and	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s) £15.83 454.043			
	Price(s) and volume(s) Aggregated information	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s) £15.83 454.043			
c)	Price(s) and volume(s)	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s) £15.83 454.043			
c)	Price(s) and volume(s) Aggregated information	Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. Price(s) Volume(s) £15.83 454.043			

e)	Date of the transaction	2017-04-26
f)	Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: July 26, 2017

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc